Complex Regional Pain Syndrome (CRPS) - Market Insights, Epidemiology and Market Forecast-2028
DelveInsight’s ‘Complex Regional Pain Syndrome (CRPS) - Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Complex Regional Pain Syndrome (CRPS) in the United States, EU5 (Germany, Spain, Italy, France and the United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, a market share of the individual therapies, the current and forecasted market size of Complex Regional Pain Syndrome (CRPS) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.
The United States
EU5 (Germany, France, Italy, Spain and the United Kingdom)
Study Period: 2017-2028
Complex Regional Pain Syndrome (CRPS) - Disease Understanding and Treatment Algorithm
According to Classification of Chronic Pain (Merskey and Bogduk 2011) of the IASP and fourth edition of CRPS guidelines, published in 2013, Harden et al. state that “CRPS-I is a syndrome characterized by a continuing (spontaneous and/or evoked) regional pain that is seemingly disproportionate in time or degree to the usual course of pain after trauma or another lesion. The pain is regional (not in a specific nerve territory or dermatome) and usually has a distal predominance of abnormal sensory, motor, sudomotor, vasomotor/edema and/or trophic findings. The syndrome shows variable progression over time. CRPS-I occurs after any form of trauma, particularly a fracture or soft tissue lesion. CRPS-II occurs after nerve damage.” There is great heterogeneity of symptoms endorsed by patients with CRPS and the clinical course varies however, the pain is the main symptom of CRPS. The pain spreads regionally, beyond a single dermatome or original insults, for example from hand to forearm. From the original International Association for the Study of Pain (IASP) criteria, Harden et al. developed the Budapest Criteria. This defined CRPS as a progressive array of painful conditions characterized by regional pain disproportionate to the inciting event in time and degree; a distal predominance of sensory, motor, sudomotor, vasomotor, and/or trophic findings; and an inability to better explain pathology by alternative diagnoses. CRPS-I, previously named reflex sympathetic dystrophy, is characterized by nociceptive pain while CRPS-II, previously named causalgia, is characterized by neuropathic pain. An additional subtype, CRPS-NOS (CRPS not otherwise specified), has been identified as CRPS which partially meets criteria but is not better explained by other conditions.
The DelveInsight Complex Regional Pain Syndrome (CRPS) market report gives the thorough understanding of the Complex Regional Pain Syndrome (CRPS) by including details such as disease definition, causes, symptoms, risk factors, and pathophysiology and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Complex Regional Pain Syndrome (CRPS) in the US, Europe, and Japan.
Complex Regional Pain Syndrome (CRPS) Epidemiology
The Complex Regional Pain Syndrome (CRPS) epidemiology division provide insights about a historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalent cases Population of Complex Regional Pain Syndrome (CRPS), Gender-specific Incidence Cases of Complex Regional Pain Syndrome (CRPS), Type specific Prevalent Cases of Complex Regional Pain Syndrome (CRPS), Number of CRPS cases in Associated Triggered Factors, Diagnosed and Treatable Cases of Complex Regional Pain Syndrome (CRPS)) scenario of Complex Regional Pain Syndrome (CRPS) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.
A retrospective cohort study by de Mos et al., in 2007, is the first ever population representative European epidemiological study. Subsequently, cases were validated for the diagnosis of CRPS with original specialist letters and information from an inquiry of general practitioners. The estimated overall new cases of CRPS was 26.2 per 100,000 person-years (95% CI: 23.0–29.7). The incidence rate of CRPS did not change significantly over time between 1996 and 2005. The disease occurrence varied profoundly with age, where the highest incidence rate was observed in the group 61–70 years of age with a mean age at diagnosis of 52.7 years. Gender-specific reporting of cases, based on the reconfirmed diagnoses, for females and males, were 40.4 and 11.9 per 100,000 person-years, respectively i.e., Females were affected at least three times more often than males (RR: 3.4, 95% CI: 2.9–3.9). The most common precipitating event for CRPS was a fracture, followed by a contusion/sprain. Upper extremities were more often affected than lower extremities, whereas the right side and left side of the body were affected with the same frequency
Complex Regional Pain Syndrome (CRPS) Drug Chapters
This segment of the Complex Regional Pain Syndrome (CRPS) report encloses the detailed analysis of late-stage (Phase-III-I) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
According to CRPS-Practical Diagnostic and Treatment Guidelines, 4th Edition - the USA, Medications trialed specifically for CRPS include calcitonin and bisphosphonates, corticosteroids, and most recently, intravenous immunoglobulin (IVIG). Treatments better studied in other related neuralgias include tricyclics, gabapentin and pregabalin, carbamazepine, opioids, clonidine, nifedipine, a-adrenergic antagonists, 5% lidocaine patch, and topical capsaicin. Interventional therapies such as nerve blocks, drug infusions, and implantable pain treatment devices have all been advocated for the treatment of CRPS. As the mechanisms of CRPS are better understood, mechanistic-based treatments should be forthcoming; but in the meanwhile, different interventional and non-interventional treatment modalities are applied empirically in a timely manner to facilitate reanimation of the affected extremity. Various blockade therapies such as sympathetic nerve blocks (SNBs), IV regional techniques (IVRAs), “other” blocks including somatic and spinal infusions, neurolytic sympathetic blockade, and implantable therapies including neurostimulators and intrathecal pumps have been available.
Currently, the treatment of CRPS is restricted to palliative care and symptom-based interventions such as Non-opioid analgesics (Paracetamol, NSAIDs, Nefopam etc.), Weak opioid analgesics (Tramadol, Codeine/Acetaminophen, Opium/PCM etc.), Strong opioid analgesics, Co-analgesics (Corticosteroids, Antiepileptics, Antidepressants, Tricyclic Antidepressants, SNRIs, Bisphosphonate, IV Bisphosphonate, Calcitonin, Ketamine etc.), Local treatment (Joint infusion of corticosteroids, Lidocaine cream, Lidocaine patch, Capsaicin, NSAIDs etc.) and others (including Physiotherapy, surgery, Psychological interventions etc.)
The process of developing preventive measures or defining the optimal treatment of a disease is usually based on an understanding of the disease’s epidemiology, identifying the pathophysiology, and targeting the etiological factors and symptoms individually. Unfortunately, in the case of CRPS, information is inadequate at many of these levels. The paucity of available randomized trials of pharmacotherapy specifically on CRPS resulted in a pragmatic approach for all health care providers.
To meet the increasing demand for the treatment of Complex Regional Pain Syndrome (CRPS), companies have shifted their focus towards the development of targeted therapies. The expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the Prevalence population of Complex Regional Pain Syndrome (CRPS) & awareness of the disease. The overall dynamics of Complex Regional Pain Syndrome (CRPS) market is anticipated to change in the coming years owing to the expected launch of emerging therapies such as Neridronate (Abiogen Pharma/Grünenthal), BHV-5000 (BioHeaven Pharmaceuticals), PPP001 (Tetra Bio-Pharma) and AXS-02 (Axsome Therapeutics) and some others, will significantly increase the market during the forecast period (2019-2028).
Complex Regional Pain Syndrome (CRPS) Market Outlook
The Complex Regional Pain Syndrome (CRPS) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Complex Regional Pain Syndrome (CRPS) in 7MM is expected to change from 2019-2028.
Complex Regional Pain Syndrome (CRPS) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The expected launch of therapies for Complex Regional Pain Syndrome (CRPS) such as Neridronate (Abiogen Pharma/Grünenthal) is the first in class, non-opioid therapeutic, and being developed as an intravenous infusion for the treatment of CRPS in the US and Europe (except Italy). It is expected to hold major market share by2028
Complex Regional Pain Syndrome (CRPS) Report Insights
Market Size and Trends
Impact of upcoming Therapies
Complex Regional Pain Syndrome (CRPS) Report Key Strengths
10 Year Forecast
Highly Analyzed Market
Key Cross Competition
Complex Regional Pain Syndrome (CRPS) Report Assessment
Current Treatment Practices
Market Drivers and Barriers
This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Complex Regional Pain Syndrome (CRPS) market
Organize sales and marketing efforts by identifying the best opportunities for Complex Regional Pain Syndrome (CRPS) market
To understand the future market competition in the Complex Regional Pain Syndrome (CRPS) market.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook